LIVE

Serial Number

88125460

Owner

Bostal Drug Delivery Co., Ltd.

Attorney

Kevin S. Costanza

Filing Date

Sep 20, 2018

Add to watchlist:

No watchlists yet

+ Create New Watchlist

View on USPTO

B Trademark

Serial Number: 88125460 • Registration: 6392216

B is a trademark filed by Bostal Drug Delivery Co., Ltd. on September 20, 2018. The trademark is classified under Class 10 (Medical Apparatus). The application is currently registered and active.

Trademark Classes

Class 10 - Medical Apparatus

Surgical, medical, dental and veterinary apparatus and instruments

Owner Contact Info

Bostal Drug Delivery Co., Ltd. (17 trademarks)

Guangzhou Science Park
Guangzhou 511300 , CN

Entity Type: 99

Legal Representation

Attorney of Record

Kevin S. Costanza

2,492 trademarks filed View all →

Correspondence Address

Kevin S. Costanza SEED IP LAW GROUP LLP

701 FIFTH AVENUE

SUITE 5400

SEATTLE, WA 98104

UNITED STATES

Trademark Details

Filing Date

September 20, 2018

Registration Date

June 22, 2021

Published for Opposition

April 6, 2021

Goods & Services

Inhalers for medical purposes; Empty inhalers for medical purposes; Medical apparatus facilitating the inhalation of pharmaceutical preparations; Medical apparatus for importing medical preparations into human bodies, namely, drug delivery devices sold empty; Implantable subcutaneous drug delivery devices sold empty; Respirators for medical purposes for artificial respiration; Disposable hypodermic syringes for medical purposes sold empty; Injection syringes for medical purposes sold empty; Injection needles for medical purposes; Medical apparatus, namely, implantable ports, nasal sprayers; Medical instruments namely, medical instruments for use in treating cancer, hypertension, heart disease, hepatitis, rheumatoid arthritis, inflammation, insomnia, nephropathy, hepatopathy, Parkinson's disease, insomnia, overactive bladder, oculopathy, encephalopathy, otopathy, stomatopathy, rhinopathy, splenopathy, pulmonary disease, dermopathy, encephalopathy, osteopathy, hemopathy, endocrinopathy, diabetes, immunological diseases, respiratory diseases

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

Jun 22, 2026 REM1

REGISTERED-PRINCIPAL REGISTER

Jun 22, 2021 R.PR

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Apr 6, 2021 NPUB

PUBLISHED FOR OPPOSITION

Apr 6, 2021 PUBO

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

Mar 17, 2021 NONP

LAW OFFICE PUBLICATION REVIEW COMPLETED

Mar 1, 2021 PREV

APPROVED FOR PUB - PRINCIPAL REGISTER

Feb 25, 2021 CNSA

EXAMINER'S AMENDMENT ENTERED

Feb 25, 2021 XAEC

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

Feb 25, 2021 GNEN

EXAMINERS AMENDMENT E-MAILED

Feb 25, 2021 GNEA

EXAMINERS AMENDMENT -WRITTEN

Feb 25, 2021 CNEA

PREVIOUS ALLOWANCE COUNT WITHDRAWN

Feb 22, 2021 ZZZX

APPROVED FOR PUB - PRINCIPAL REGISTER

Feb 22, 2021 CNSA

TEAS/EMAIL CORRESPONDENCE ENTERED

Feb 20, 2021 TEME

CORRESPONDENCE RECEIVED IN LAW OFFICE

Feb 19, 2021 CRFA

TEAS REQUEST FOR RECONSIDERATION RECEIVED

Feb 19, 2021 ERFR

NOTIFICATION OF FINAL REFUSAL EMAILED

Aug 21, 2020 GNFN

FINAL REFUSAL E-MAILED

Aug 21, 2020 GNFR

FINAL REFUSAL WRITTEN

Aug 21, 2020 CNFR

TEAS/EMAIL CORRESPONDENCE ENTERED

Aug 17, 2020 TEME

CORRESPONDENCE RECEIVED IN LAW OFFICE

Aug 17, 2020 CRFA

TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

Aug 10, 2020 ERSI

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

Mar 28, 2020 CHAN

TEAS CHANGE OF CORRESPONDENCE RECEIVED

Mar 28, 2020 TCCA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

Mar 28, 2020 ARAA

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

Mar 28, 2020 REAP

TEAS CHANGE OF OWNER ADDRESS RECEIVED

Mar 28, 2020 COAR

NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED

Feb 17, 2020 GNS2

INQUIRY TO SUSPENSION E-MAILED

Feb 17, 2020 GNSI

SUSPENSION INQUIRY WRITTEN

Feb 17, 2020 CNSI

SUSPENSION CHECKED - TO ATTORNEY FOR ACTION

Jan 30, 2020 RCCK

ASSIGNED TO LIE

Jan 17, 2020 ALIE

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

Jul 1, 2019 GNS3

LETTER OF SUSPENSION E-MAILED

Jul 1, 2019 GNSL

SUSPENSION LETTER WRITTEN

Jul 1, 2019 CNSL

TEAS/EMAIL CORRESPONDENCE ENTERED

Jun 21, 2019 TEME

CORRESPONDENCE RECEIVED IN LAW OFFICE

Jun 20, 2019 CRFA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

Jun 20, 2019 TROA

NOTIFICATION OF NON-FINAL ACTION E-MAILED

Dec 21, 2018 GNRN

NON-FINAL ACTION E-MAILED

Dec 21, 2018 GNRT

NON-FINAL ACTION WRITTEN

Dec 21, 2018 CNRT

ASSIGNED TO EXAMINER

Dec 21, 2018 DOCK

NOTICE OF DESIGN SEARCH CODE E-MAILED

Sep 27, 2018 MDSM

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Sep 26, 2018 NWOS

NEW APPLICATION ENTERED

Sep 24, 2018 NWAP

Related Trademarks

More from this Owner

ZPHERES

GELEEPOT

More in Same Class

GEMCITABINE IN 0.9% SODIUM CHLORIDE INJECTION 1,300 MG PER 130 ML (10 MG/ML)

LICENSED BIEDERMANN TECHNOLOGY

GEMCITABINE IN 0.9% SODIUM CHLORIDE INJECTION 1,600 MG PER 160 ML (10 MG/ML)

GEMCITABINE IN 0.9% SODIUM CHLORIDE INJECTION 1,900 MG PER 190 ML (10 MG/ML)

GEMCITABINE IN 0.9% SODIUM CHLORIDE INJECTION 2,000 MG PER 200 ML (10 MG/ML)

GEMCITABINE IN 0.9% SODIUM CHLORIDE INJECTION 2,200 MG PER 220 ML (10 MG/ML)